Jackson Creek Investment Advisors LLC Sells 26 Shares of Eli Lilly and Company (NYSE:LLY)

Jackson Creek Investment Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 3.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 800 shares of the company’s stock after selling 26 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $466,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. JGP Wealth Management LLC increased its position in Eli Lilly and Company by 0.9% during the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after acquiring an additional 16 shares during the period. Patton Albertson Miller Group LLC increased its position in Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after acquiring an additional 17 shares during the period. Valley Wealth Managers Inc. increased its position in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after acquiring an additional 17 shares during the period. Sandy Cove Advisors LLC increased its position in Eli Lilly and Company by 0.8% during the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after acquiring an additional 17 shares during the period. Finally, Lathrop Investment Management Corp increased its position in Eli Lilly and Company by 1.2% during the third quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock worth $793,000 after acquiring an additional 18 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 6.0 %

LLY opened at $781.56 on Wednesday. The company’s 50 day moving average is $761.41 and its 200-day moving average is $669.21. Eli Lilly and Company has a 1-year low of $392.26 and a 1-year high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market cap of $742.61 billion, a P/E ratio of 134.75, a PEG ratio of 1.61 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the company earned $1.62 EPS. The firm’s revenue was up 26.0% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LLY shares. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Bank of America increased their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $733.65.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.